Visualization of SV2A conformations in situ by the use of Protein Tomography

Biochemical and Biophysical Research Communications

Volumn 375, Issue 4, 2008, Pages 491-495

  Lynch, Berkley A ^a   Matagne, Alain ^a   Brännström, Annika ^b   von Euler, Anne ^b   Jansson, Magnus ^b   Hauzenberger, Elenor ^b   Söderhäll, J Arvid ^b  

^a UCB PHARMA   (Belgium)

^b Protein Tomography Lab   (Sweden)

Author keywords

MFS class transporter; Protein Tomography; SV2A; Synaptic vesicle

Indexed keywords

BINDING PROTEIN; ETIRACETAM; SODIUM CHLORIDE; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CYTOPLASM; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TOMOGRAPHY; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; TOMOGRAPHY;

ANIMALS; ANTICONVULSANTS; BRAIN CHEMISTRY; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, IMMUNOELECTRON; NERVE TISSUE PROTEINS; PIRACETAM; PROTEIN CONFORMATION;

EID: 51949114854     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.07.145     Document Type: Article

References (21)

1. Buckley K., and Kelly R.B. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J. Cell Biol. 100 (1985) 1284-1294
2. Bajjalieh S.M., Frantz G.D., Weimann J.M., McConnell S.K., and Scheller R.H. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci. 14 (1994) 5223-5235
3. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
4. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., and Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
5. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. USA 96 (1999) 15268-15273
6. Xu T., and Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell Biol. 3 (2001) 691-698
7. Custer K.L., Austin N.S., Sullivan J.M., and Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26 (2006) 1303-1313
8. Noyer M., Gillard M., Matagne A., Hénichart J.-P., and Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
9. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA 101 (2004) 9861-9866
10. Bajjalieh S.M., Peterson K., Shinghal R., and Scheller R.H. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257 (1992) 1271-1273
11. Janz R., Goda Y., Geppert M., Missler M., and Sudhof T.C. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24 (1999) 1003-1016
12. Kaback H.R., Dunten R., Frillingos S., Venkatesan P., Kwaw I., Zhang W., and Ermolova N. Site-directed alkylation and the alternating access model for LacY. Proc. Natl. Acad. Sci. USA 104 (2007) 491-494
13. Skoglund U., Ofverstedt L.G., Burnett R.M., and Bricogne G. Maximum- entropy three-dimensional reconstruction with deconvolution of the contrast transfer function: a test application with adenovirus. J. Struct. Biol. 117 (1996) 173-188
14. Rullgård H., Öktem O., and Skoglund U. A componentwise iterated relative entropy regularization method with updated prior and regularization parameter. Inverse Probl. 23 (2007) 2121-2139
15. Fanelli D., and Öktem O. Electron tomography: a short overview with an emphasis on the absorption potential model for the forward problem. Inverse Probl. 24 (2008) 013001 (51 pp.)
16. Öktem O. In: Censor Y., Jiang M., and Loui A.K. (Eds). Mathematical Methods in Biomedical Imaging and Intensity-modulated Radiation Therapy (IMRT) (2008), Birkhauser Verlag
17. Lammerts van Bueren J.J., Bleeker W.K., Brännström A., von Euler A., Jansson M., Peipp M., Schneider-Merck T., Valerius T., v de Winkel J.G.J., and Parren P.W.H.I. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc. Natl. Acad. Sci. USA 105 (2008) 6109-6114
18. Tokuyasu K.T. Immunochemistry on ultrathin frozen sections. Histochem. J. 4 (1980) 381-403
19. Mirza O., Guan L., Verner G., Iwata S., and Kaback H.R. Structural evidence for induced fit and a mechanism for sugar/H+ symport in LacY. EMBO J. 25 (2006) 1177-1183
20. Humphrey W., Dalke A., and Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 14 (1996) 33-38
21. Hirai T., Heymann J.A., Maloney P.C., and Subramaniam S. Structural model for 12-helix transporters belonging to the major facilitator superfamily. J. Bacteriol. 185 (2003) 1712-1718